 - Serological positivity for Hepatitis C, B or known HIV infection. Viral serological testing is not mandated for study entry, but considered standard of care. Positive test results for chronic HBV infection defined as positive HBsAg serology will not be eligible. Patients with occult or prior HBV infection defined as negative HBsAg and positive total HBcAb will not be eligible as one would normally monitor HBV DNA serially and add lamivudine if copy number became detectable. There is an interaction between lamivudine and bortezomib. Reactivation of latent infection has been reported with the use of bortezomib in this population along obviously with the well recognised reactivation following R-CHOP. For these patient safety reasons, these patients should be excluded. Patients who have protective titres of hepatitis B surface antibody HBSAb after vaccination are eligible. Positive test results for hepatitis C hepatitis C virus HCV antibody serology testing will not be eligible. 